Intellia Therapeutics Inc. (NASDAQ:NTLA)’s traded shares stood at 1.24 million during the last session, with the company’s beta value hitting 1.89. At the close of trading, the stock’s price was $40.55, to imply a decrease of -0.81% or -$0.33 in intraday trading. The NTLA share’s 52-week high remains $78.58, putting it -93.79% down since that peak but still an impressive 20.0% since price per share fell to its 52-week low of $32.44. The company has a valuation of $3.73B, with an average of 1.57 million shares in intraday trading volume over the past 10 days and average of 1.20 million shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Intellia Therapeutics Inc. (NTLA), translating to a mean rating of 1.90. Of 28 analyst(s) looking at the stock, 0 analyst(s) give NTLA a Sell rating. 2 of those analysts rate the stock as Overweight while 4 advise Hold as 22 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$1.39.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Intellia Therapeutics Inc. (NASDAQ:NTLA) trade information
After registering a -0.81% downside in the last session, Intellia Therapeutics Inc. (NTLA) has traded red over the past five days. The stock hit a weekly high of 41.55 this Thursday, 03/16/23, dropping -0.81% in its intraday price action. The 5-day price performance for the stock is 8.36%, and -0.56% over 30 days. With these gigs, the year-to-date price performance is 16.22%. Short interest in Intellia Therapeutics Inc. (NASDAQ:NTLA) saw shorts transact 7.35 million shares and set a 6.22 days time to cover.
Analysts on Wall Street suggest a consensus price target of $96.44, implying an increase of 57.95% to the stock’s current value. The extremes give us $39.00 and $168.00 for target low and target high price respectively. As such, NTLA has been trading -314.3% off suggested target high and 3.82% from its likely low.
Intellia Therapeutics Inc. (NTLA) estimates and forecasts
Looking at statistics comparing Intellia Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. Intellia Therapeutics Inc. (NTLA) shares are -36.52% down over the last 6 months, with its year-to-date growth rate lower than industry average at 5.68% against 9.40%. Revenue is forecast to shrink -27.50% this quarter before jumping 28.10% for the next one. The rating firms project that company’s revenue will grow 57.20% compared to the previous financial year.
Revenue forecast for the current quarter as set by 21 analysts is $11.33 million. Meanwhile, for the quarter ending Mar 2023, a total of 15 analyst(s) estimate revenue growth to $12.53 million.Earnings reports from the last fiscal year show that sales brought in $12.85 million and $11.25 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -11.90% before jumping 11.40% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -26.80% for the past 5-year period. While 2023 is set for a -63.00% return in earnings, projections for the next 5 years are at 30.00% annually.
Intellia Therapeutics Inc. has its next earnings report out between May 03 and May 08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Intellia Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Intellia Therapeutics Inc. (NASDAQ:NTLA)’s Major holders
Intellia Therapeutics Inc. insiders hold 6.27% of total outstanding shares, with institutional holders owning 80.12% of the shares at 85.48% float percentage. In total, 80.12% institutions holds shares in the company, led by ARK Investment Management, LLC. As of Dec 30, 2022, the company held over 9.42 million shares (or 11.97% of shares), all amounting to roughly $328.69 million.
The next major institution holding the largest number of shares is Vanguard Group, Inc. (The) with 6.62 million shares, or about 8.41% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $370.31 million.
We also have ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Intellia Therapeutics Inc. (NTLA) shares. Going by data provided on Dec 30, 2022, ARK ETF Tr-ARK Innovation ETF holds roughly 6.54 million shares. This is just over 8.32% of the total shares, with a market valuation of $228.34 million. Data from the same date shows that the other fund manager holds a little less at 2.06 million, or 2.62% of the shares, all valued at about 115.18 million.